In this context, we have shown that SARS-CoV-2 spike glycoprotein-based vaccines have the potential to interact with tumor suppressor proteins, promote inflammation, activate oncogenic pathways, and disrupt the fine-tuning of the immune response. These dysregulated mechanisms and signaling pathways underlie most types of cancer. This evidence concerns the gene TCHP and cancer.